Andere Sprachen 2seventy bio, Inc.

Aktien

A3C5JL

US9013841070

TSVT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
4,6 ^USD	+0,88 %		+7,73 %	+7,73 %

19.04.	US FDA ordnet Aktualisierung der Kennzeichnung von CAR-T-Krebstherapien an	RE
05.04.	Bristol-Myers Squibb, 2seventy Bio: FDA genehmigt Erweiterung der Indikation für Myelom-Behandlung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

US FDA mandates label updates on CAR-T cancer therapies	19.04.
FDA Approves BMS And J&J CAR-T Cell Therapies For The Earlier Treatment Of Multiple Myeloma	17.04.
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy	08.04.
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05.04.
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	05.04.
Bristol Myers : la FDA valide Abecma dans le myélome multiple	05.04.
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05.04.
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05.04.
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	05.04.
2seventy bio : Corporate Presentation April 2024	01.04.
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron	01.04.
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..	01.04.
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.	01.04.
Bristol Myers Squibb Gets EU OK for Cancer Treatment	20.03.
Engine Capital Nominates Candidates to the Board of 2seventy bio	20.03.
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors	20.03.
2seventy bio, Inc. Announces Board Appointments	20.03.
Thinking about buying stock in Solidion Technology, Nuvei, 2Seventy Bio, Aeye, or DHC Acquisition?	18.03.
Top Premarket Gainers	18.03.
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy	18.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen 2seventy bio, Inc.

Aktien

A3C5JL

US9013841070

TSVT

Andere Sprachen

Filter